Загрузка...

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

BACKGROUND: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Donahue, Renee N., Lepone, Lauren M., Grenga, Italia, Jochems, Caroline, Fantini, Massimo, Madan, Ravi A., Heery, Christopher R., Gulley, James L., Schlom, Jeffrey
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2017
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5320726/
https://ncbi.nlm.nih.gov/pubmed/28239472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0220-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!